Published in Eur J Cancer on June 05, 2006
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol (2011) 1.64
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer (2008) 1.37
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer (2010) 1.34
Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol (2008) 1.22
Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res (2012) 1.21
Management of chemotherapy-associated febrile neutropenia. Br J Cancer (2009) 1.20
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer (2009) 1.16
Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol (2008) 1.15
Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med (2013) 1.13
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer (2010) 1.11
Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements. Mol Ther (2008) 1.10
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer (2010) 1.07
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer (2013) 1.05
Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer (2009) 1.03
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study. Eur J Cancer Care (Engl) (2008) 1.02
Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer (2009) 1.02
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer (2010) 0.95
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica (2013) 0.94
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res (2009) 0.93
Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J (2008) 0.93
Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern. Support Care Cancer (2008) 0.93
Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol (2008) 0.93
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer (2015) 0.92
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res (2008) 0.91
Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care (Engl) (2013) 0.90
Disclosing gaps between supportive and palliative care: the past 20 years. Support Care Cancer (2007) 0.90
Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. Br J Cancer (2009) 0.90
Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis (2011) 0.89
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol (2010) 0.89
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One (2014) 0.88
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? Support Care Cancer (2014) 0.87
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC Cancer (2010) 0.85
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer (2010) 0.85
The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer (2009) 0.85
Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care (2010) 0.85
Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest (2014) 0.85
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol (2010) 0.84
Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care (Engl) (2010) 0.84
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. Br J Cancer (2010) 0.84
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol (2010) 0.84
Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplant (2013) 0.84
Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Theranostics (2014) 0.83
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice. Support Care Cancer (2013) 0.83
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol (2015) 0.83
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. Br J Cancer (2007) 0.82
The critically-ill pediatric hemato-oncology patient: epidemiology, management, and strategy of transfer to the pediatric intensive care unit. Ann Intensive Care (2012) 0.82
Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. Ecancermedicalscience (2013) 0.82
Zarzio(®), biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer (2015) 0.82
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer (2010) 0.80
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Support Care Cancer (2008) 0.80
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol (2016) 0.79
Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer (2014) 0.79
Trends in neutropenia-related inpatient events. J Oncol Pract (2012) 0.79
Breast cancer: Improved care through effective management of febrile neutropenia. Foreword. Br J Cancer (2009) 0.79
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol (2013) 0.79
[Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr (2008) 0.78
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs (2015) 0.78
Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus (2015) 0.78
Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer Manag Res (2013) 0.78
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag (2013) 0.78
Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Invest New Drugs (2015) 0.77
Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. Pharm Pract (Granada) (2010) 0.77
Murine model of chemotherapy-induced extraintestinal pathogenic Escherichia coli translocation. Infect Immun (2015) 0.77
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients. Clinics (Sao Paulo) (2016) 0.77
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr (2012) 0.76
Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted. J Med Chem (2014) 0.76
Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J (2011) 0.76
Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer (2015) 0.76
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs (2013) 0.76
Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. Support Care Cancer (2013) 0.75
Effects of low-dose G-CSF formulation on hematology in healthy horses after long-distance transportation. J Vet Med Sci (2015) 0.75
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer. Mol Clin Oncol (2015) 0.75
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol (2011) 0.75
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Support Care Cancer (2017) 0.75
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study. Adv Ther (2016) 0.75
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol (2008) 0.75
Bacteriophages from ExPEC Reservoirs Kill Pandemic Multidrug-Resistant Strains of Clonal Group ST131 in Animal Models of Bacteremia. Sci Rep (2017) 0.75
Unilateral lymphadenopathy due to the use of granulocyte colony stimulating factor. BMJ Case Rep (2011) 0.75
Supportive care in hemato-oncology: a review in light of the latest guidelines. Turk J Haematol (2012) 0.75
Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mol Clin Oncol (2016) 0.75
Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan. J Blood Med (2017) 0.75
Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leuk Lymphoma (2011) 0.75
Supportive therapy in medical therapy of head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.75
Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. Mol Clin Oncol (2016) 0.75
Adjuvant radiochemotherapy in locally advanced gastric cancer : Treatment results and analysis of possible prognostic factors. Strahlenther Onkol (2017) 0.75
The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Support Care Cancer (2013) 0.75
A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Support Care Cancer (2014) 0.75
Neoadjuvant chemoradiotherapy, sepsis and neutrophil levels following radical excision of rectal cancer. Int J Colorectal Dis (2010) 0.75
Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. Support Care Cancer (2016) 0.75
Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. Int J Clin Oncol (2015) 0.75
1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. World J Oncol (2015) 0.75
Myeloid growth factor therapy in malignant lymphomas--a 5-year retrospective study from Hungary. Support Care Cancer (2010) 0.75
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Front Pharmacol (2017) 0.75
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
The uncertainty principle and industry-sponsored research. Lancet (2000) 7.75
Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet (1999) 5.37
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst (1992) 4.19
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA (1996) 4.13
Comorbidity and functional status are independent in older cancer patients. J Clin Oncol (1998) 4.11
Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol (2005) 3.98
Assessing Wolf motor function test as outcome measure for research in patients after stroke. Stroke (2001) 3.79
Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci U S A (1999) 3.71
The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: a randomised controlled trial. BMJ (1998) 3.63
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol (2001) 3.44
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A (1988) 3.23
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost (2007) 3.22
New equities of information in an electronic age. BMJ (1995) 3.20
In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk reduction rather than unbridled sex. AIDS Care (2002) 3.01
Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol (2003) 3.00
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg (1998) 2.90
Factors affecting home delivery in the Kathmandu Valley, Nepal. Health Policy Plan (1998) 2.68
Letter: Eye injuries in hockey. Can Med Assoc J (1974) 2.52
Sustaining safe sex: a longitudinal study of a sample of homosexual men. AIDS (1993) 2.35
Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat (1998) 2.28
Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol (1998) 2.27
A visual pigment expressed in both rod and cone photoreceptors. Neuron (2001) 2.17
A comparative study of the postoperative allogeneic blood-sparing effect of tranexamic acid versus acute normovolemic hemodilution after total knee replacement. Anesth Analg (1999) 2.17
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12
Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion (1993) 2.04
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol (2000) 1.96
Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood (1995) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod (2006) 1.93
Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage (1999) 1.89
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol (2002) 1.87
Molecular strategies for improving waterlogging tolerance in plants. J Exp Bot (2000) 1.84
Abdominal obesity and breast cancer risk. Ann Intern Med (1990) 1.83
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82
When immigrants are not migrants: counting arrivals of the foreign born using the U.S. census. Int Migr Rev (1998) 1.80
Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med (1998) 1.75
Hemiarthroplasty versus internal fixation for displaced intracapsular hip fractures in the elderly. A randomised trial of 455 patients. J Bone Joint Surg Br (2002) 1.73
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. MedGenMed (2000) 1.71
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med (1997) 1.65
Posthumous diagnosis of long QT syndrome from neonatal screening cards. Heart Rhythm (2010) 1.65
Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol (1998) 1.64
Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA (1998) 1.62
The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia (2012) 1.61
Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation. Nature (1976) 1.59
Pseudoascites--still a diagnostic pitfall. Isr Med Assoc J (2001) 1.59
A scale of optimism-scepticism in the context of HIV treatments. AIDS Care (2000) 1.58
The association between anxiety and psychopathy dimensions in children. J Abnorm Child Psychol (1999) 1.58
Brief report: intragenic deletion of the KALIG-1 gene in Kallmann's syndrome. N Engl J Med (1992) 1.58
Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry (1980) 1.58
Invasive infection due to penicillium species other than P. marneffei. J Infect (2002) 1.58
The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. J Am Coll Surg (2001) 1.53
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood (1997) 1.52
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol (1993) 1.51
Quantified superiority of cognitive behaviour therapy to antidepressant drugs: a challenge to an earlier meta-analysis. Acta Psychiatr Scand (2008) 1.51
Modulation of an idioventricular rhythm by vagal tone. J Am Coll Cardiol (1988) 1.49
HIV risk and communication between regular partners in a cohort of HIV-negative gay men. AIDS Care (2006) 1.49
Obesity and body fat distribution and breast cancer prognosis. Cancer (1991) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Trends in heterosexual tertiary students' knowledge of HIV and intentions to avoid people who might have HIV. AIDS Care (1996) 1.45
HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene (1989) 1.41
Beclomethasone dipropionate aerosol in childhood asthma. Arch Dis Child (1973) 1.41
Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung Cancer (2007) 1.41
Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost (2014) 1.39
[Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause]. Dtsch Med Wochenschr (1992) 1.39
GASTRIC AND DUODENAL PERFORATION DURING HOSPITAL TREATMENT. Ann Surg (1936) 1.39
Patients' perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) (2009) 1.38
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.38
Chronic illness and functional limitation in Ontario children: findings of the Ontario Child Health Study. CMAJ (1986) 1.36
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol (2010) 1.35
Household organization and the interregional variation of out-migration rates. Demography (1988) 1.35
Mozambique child soldier life outcome study: lessons learned in rehabilitation and reintegration efforts. Glob Public Health (2006) 1.34
Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann Hum Genet (1998) 1.34
Effects of season and distance moved during loading on transport losses of market-weight pigs in two commercially available types of trailer. J Anim Sci (2008) 1.34
The importance of callous-unemotional traits for extending the concept of psychopathy to children. J Abnorm Psychol (2000) 1.34
Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2000) 1.33
Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol (2000) 1.31
The mechanism of the rhythmic changes in the calibre of the bronchi during respiration. J Physiol (1936) 1.31
pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F. Oncogene (1998) 1.30
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS (1999) 1.29